David Kirske is EVP, Chief Financial Officer of CTI BIOPHARMA CORP. Currently has a direct ownership of 0 shares of CTIC, which is worth approximately $0. The most recent transaction as insider was on Jun 26, 2023, when has been sold 17,547 shares (Common Stock) at a price of $9.1 per share, resulting in proceeds of $159,677. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

DAVID KIRSKE Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 26 2023
SELL
Disposition due to a tender of shares in a change of control transaction
$159,677 $9.1 p/Share
17,547 Reduced 100.0%
0 Common Stock
Jan 03 2023
SELL
Open market or private sale
$162,396 $6.01 p/Share
27,021 Reduced 61.21%
17,127 Common Stock
Jan 03 2023
BUY
Exercise of conversion of derivative security
$25,669 $0.95 p/Share
27,021 Added 37.97%
44,148 Common Stock
Dec 30 2022
SELL
Open market or private sale
$83,082 $6.0 p/Share
13,847 Reduced 44.71%
17,127 Common Stock
Dec 30 2022
BUY
Exercise of conversion of derivative security
$13,154 $0.95 p/Share
13,847 Added 43.24%
18,174 Common Stock
Dec 30 2022
BUY
Grant, award, or other acquisition
$1,093 $5.11 p/Share
214 Added 1.23%
17,127 Common Stock
Dec 29 2022
SELL
Open market or private sale
$79,044 $6.0 p/Share
13,174 Reduced 43.79%
16,913 Common Stock
Dec 29 2022
BUY
Exercise of conversion of derivative security
$12,515 $0.95 p/Share
13,174 Added 30.45%
30,087 Common Stock
Oct 04 2022
SELL
Open market or private sale
$13,202 $6.26 p/Share
2,109 Reduced 11.09%
16,913 Common Stock
Oct 04 2022
BUY
Exercise of conversion of derivative security
$2,004 $0.95 p/Share
2,109 Added 10.74%
17,522 Common Stock
Oct 03 2022
SELL
Open market or private sale
$1,875 $6.25 p/Share
300 Reduced 1.74%
16,913 Common Stock
Oct 03 2022
BUY
Exercise of conversion of derivative security
$285 $0.95 p/Share
300 Added 1.71%
17,213 Common Stock
Sep 30 2022
SELL
Open market or private sale
$846,038 $6.05 p/Share
139,841 Reduced 89.21%
16,913 Common Stock
Sep 30 2022
BUY
Exercise of conversion of derivative security
$132,849 $0.95 p/Share
139,841 Added 47.15%
156,754 Common Stock
Sep 29 2022
SELL
Open market or private sale
$5,409 $6.01 p/Share
900 Reduced 5.05%
16,913 Common Stock
Sep 29 2022
BUY
Exercise of conversion of derivative security
$855 $0.95 p/Share
900 Added 5.02%
17,013 Common Stock
Sep 16 2022
SELL
Open market or private sale
$136,004 $6.02 p/Share
22,592 Reduced 57.19%
16,913 Common Stock
Sep 16 2022
BUY
Exercise of conversion of derivative security
$21,462 $0.95 p/Share
22,592 Added 36.38%
39,505 Common Stock
Jun 30 2022
BUY
Grant, award, or other acquisition
$20,174 $2.12 p/Share
9,516 Added 36.01%
16,913 Common Stock
Jun 17 2022
SELL
Open market or private sale
$367,800 $6.13 p/Share
60,000 Reduced 89.02%
7,397 Common Stock
Jun 17 2022
BUY
Exercise of conversion of derivative security
$129,000 $2.15 p/Share
60,000 Added 51.11%
57,397 Common Stock
Jun 14 2022
SELL
Open market or private sale
$55,000 $5.5 p/Share
10,000 Reduced 57.48%
7,397 Common Stock
Jun 14 2022
BUY
Exercise of conversion of derivative security
$9,500 $0.95 p/Share
10,000 Added 36.5%
17,397 Common Stock
Dec 31 2021
BUY
Grant, award, or other acquisition
$3,834 $2.11 p/Share
1,817 Added 19.72%
7,397 Common Stock
Jun 30 2021
BUY
Grant, award, or other acquisition
$3,778 $2.12 p/Share
1,782 Added 24.21%
5,580 Common Stock
DK

David Kirske

EVP, Chief Financial Officer
Seattle, WA

Track Institutional and Insider Activities on CTIC

Follow CTI BIOPHARMA CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTIC shares.

Notify only if

Insider Trading

Get notified when an Cti Biopharma Corp insider buys or sells CTIC shares.

Notify only if

News

Receive news related to CTI BIOPHARMA CORP

Track Activities on CTIC